Analytical Data
-
Gene name
CHRNa6
- Application
-
Alternative Names
CHRNa6；Neuronal acetylcholine receptor subunit alpha-6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15825
-
Expression Region
26-239aa
-
AA Sequence
MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSKGCV GCATEERLFH KLFSHYNQFI RPVENVSDPV TVHFEVAITQ LANVDEVNQI METNLWLRHI WNDYKLRWDP MEYDGIETLR VPADKIWKPD IVLYNNAVGD FQVEGKTKAL LKYNGMITWT PPAIFKSSCP MDITFFPFDH QNCSLKFGSW TYDKAEIDLL IIGSKVDMND FWENSEWEII DASGYKHDIK YNCCEEIYTD ITYSFYIRRL
-
Molecular Weight
29 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on CHRNa6 recombinant proteins has gained significant attention due to their potential implications in neuroscience and pharmacology. CHRNa6, a subtype of nicotinic acetylcholine receptors, plays a crucial role in neurotransmission and is implicated in various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and addiction. Understanding the structure and function of CHRNa6 at the molecular level is essential for developing targeted therapies. Recombinant protein techniques allow scientists to express and purify CHRNa6, facilitating detailed investigation into its biophysical properties, ligand binding sites, and interaction with various pharmacological agents. By using advanced methods such as X-ray crystallography and cryo-electron microscopy, researchers aim to elucidate the receptor’s conformational dynamics and identify potential therapeutic targets. Additionally, studying CHRNa6 can provide insights into the development of more effective drugs with fewer side effects, ultimately contributing to improved treatments for neurological disorders. The ongoing research in this field continues to enhance our understanding of cholinergic signaling pathways and their relevance to human health.
